– UK, Weybridge – Haleon plc (LON: HLN / NYSE: HLN) announced the appointment of current Board member Vindi Banga as Chair of the Board of Directors with effect from 1 January 2026 to succeed Sir Dave Lewis, who will resign from the Board.
About Vindi Banga
Vindi Banga has extensive international Board experience. He is currently Chair of UK Government Investments Limited (UKGI) and has previously served as Senior Independent Director at GSK and Marks and Spencer plc. Vindi is a partner at CD&R, a leading private investment firm, where he has chaired and served on the boards of several of the firm’s portfolio companies. He is the Chair of the Council of Imperial College London.
About Haleon
Haleon is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health, and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren – are built on trusted science, innovation, and deep human understanding.
For more: https://www.haleon.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.